ID   CHST3_HUMAN             Reviewed;         479 AA.
AC   Q7LGC8; O75099; Q52M30;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   10-MAY-2017, entry version 129.
DE   RecName: Full=Carbohydrate sulfotransferase 3;
DE            EC=2.8.2.17;
DE   AltName: Full=Chondroitin 6-O-sulfotransferase 1;
DE            Short=C6ST-1;
DE   AltName: Full=Chondroitin 6-sulfotransferase;
DE   AltName: Full=Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-sulfotransferase 0;
DE            Short=GST-0;
GN   Name=CHST3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=9714738; DOI=10.1016/S0167-4781(98)00089-X;
RA   Fukuta M., Kobayashi Y., Uchimura K., Kimata K., Habuchi O.;
RT   "Molecular cloning and expression of human chondroitin 6-
RT   sulfotransferase.";
RL   Biochim. Biophys. Acta 1399:57-61(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Placenta;
RX   PubMed=9883891; DOI=10.1016/S0014-5793(98)01532-4;
RA   Tsutsumi K., Shimakawa H., Kitagawa H., Sugahara K.;
RT   "Functional expression and genomic structure of human chondroitin 6-
RT   sulfotransferase.";
RL   FEBS Lett. 441:235-241(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-357.
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   VARIANT SEDCJD GLN-304.
RX   PubMed=15215498; DOI=10.1073/pnas.0400334101;
RA   Thiele H., Sakano M., Kitagawa H., Sugahara K., Rajab A., Hoehne W.,
RA   Ritter H., Leschik G., Nuernberg P., Mundlos S.;
RT   "Loss of chondroitin 6-O-sulfotransferase-1 function results in severe
RT   human chondrodysplasia with progressive spinal involvement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:10155-10160(2004).
RN   [5]
RP   VARIANTS SEDCJD TRP-222; PRO-259; PRO-307 AND LYS-372, VARIANT
RP   GLN-357, AND CHARACTERIZATION OF VARIANTS SEDCJD TRP-222 AND PRO-259.
RX   PubMed=18513679; DOI=10.1016/j.ajhg.2008.05.006;
RA   Hermanns P., Unger S., Rossi A., Perez-Aytes A., Cortina H.,
RA   Bonafe L., Boccone L., Setzu V., Dutoit M., Sangiorgi L., Pecora F.,
RA   Reicherter K., Nishimura G., Spranger J., Zabel B., Superti-Furga A.;
RT   "Congenital joint dislocations caused by carbohydrate sulfotransferase
RT   3 deficiency in recessive Larsen syndrome and humero-spinal
RT   dysostosis.";
RL   Am. J. Hum. Genet. 82:1368-1374(2008).
RN   [6]
RP   ERRATUM.
RA   Hermanns P., Unger S., Rossi A., Perez-Aytes A., Cortina H.,
RA   Bonafe L., Boccone L., Setzu V., Dutoit M., Sangiorgi L., Pecora F.,
RA   Reicherter K., Nishimura G., Spranger J., Zabel B., Superti-Furga A.;
RL   Am. J. Hum. Genet. 83:293-293(2008).
CC   -!- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl
CC       sulfate (PAPS) as sulfonate donor to catalyze the transfer of
CC       sulfate to position 6 of the N-acetylgalactosamine (GalNAc)
CC       residue of chondroitin. Chondroitin sulfate constitutes the
CC       predominant proteoglycan present in cartilage and is distributed
CC       on the surfaces of many cells and extracellular matrices. Can also
CC       sulfate Gal residues of keratan sulfate, another
CC       glycosaminoglycan, and the Gal residues in sialyl N-
CC       acetyllactosamine (sialyl LacNAc) oligosaccharides. May play a
CC       role in the maintenance of naive T-lymphocytes in the spleen.
CC       {ECO:0000269|PubMed:9714738, ECO:0000269|PubMed:9883891}.
CC   -!- CATALYTIC ACTIVITY: 3'-phosphoadenylyl sulfate + chondroitin =
CC       adenosine 3',5'-bisphosphate + chondroitin 6'-sulfate.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000250};
CC       Single-pass type II membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Widely expressed in adult tissues. Expressed
CC       in heart, placenta, skeletal muscle and pancreas. Also expressed
CC       in various immune tissues such as spleen, lymph node, thymus and
CC       appendix. {ECO:0000269|PubMed:9714738}.
CC   -!- DISEASE: Spondyloepiphyseal dysplasia with congenital joint
CC       dislocations (SEDCJD) [MIM:143095]: A bone dysplasia clinically
CC       characterized by dislocation of the knees and/or hips at birth,
CC       clubfoot, elbow joint dysplasia with subluxation and limited
CC       extension, short stature, and progressive kyphosis developing in
CC       late childhood. The disorder is usually evident at birth, with
CC       short stature and multiple joint dislocations or subluxations that
CC       dominate the neonatal clinical and radiographic picture. During
CC       childhood, the dislocations improve, both spontaneously and with
CC       surgical treatment, and features of spondyloepiphyseal dysplasia
CC       become apparent, leading to arthritis of the hips and spine with
CC       intervertebral disk degeneration, rigid kyphoscoliosis, and trunk
CC       shortening by late childhood. {ECO:0000269|PubMed:15215498,
CC       ECO:0000269|PubMed:18513679}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 1 family.
CC       Gal/GlcNAc/GalNAc subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB012192; BAA32576.1; -; mRNA.
DR   EMBL; AB017915; BAA36348.1; -; mRNA.
DR   EMBL; BC093690; AAH93690.1; -; mRNA.
DR   EMBL; BC104856; AAI04857.1; -; mRNA.
DR   CCDS; CCDS7312.1; -.
DR   RefSeq; NP_004264.2; NM_004273.4.
DR   RefSeq; XP_006718138.1; XM_006718075.3.
DR   RefSeq; XP_011538671.1; XM_011540369.2.
DR   UniGene; Hs.158304; -.
DR   ProteinModelPortal; Q7LGC8; -.
DR   SMR; Q7LGC8; -.
DR   BioGrid; 114855; 5.
DR   IntAct; Q7LGC8; 1.
DR   STRING; 9606.ENSP00000362207; -.
DR   iPTMnet; Q7LGC8; -.
DR   PhosphoSitePlus; Q7LGC8; -.
DR   BioMuta; CHST3; -.
DR   DMDM; 116241297; -.
DR   EPD; Q7LGC8; -.
DR   MaxQB; Q7LGC8; -.
DR   PaxDb; Q7LGC8; -.
DR   PeptideAtlas; Q7LGC8; -.
DR   PRIDE; Q7LGC8; -.
DR   Ensembl; ENST00000373115; ENSP00000362207; ENSG00000122863.
DR   GeneID; 9469; -.
DR   KEGG; hsa:9469; -.
DR   UCSC; uc001jsn.4; human.
DR   CTD; 9469; -.
DR   DisGeNET; 9469; -.
DR   GeneCards; CHST3; -.
DR   GeneReviews; CHST3; -.
DR   HGNC; HGNC:1971; CHST3.
DR   HPA; HPA047523; -.
DR   HPA; HPA055704; -.
DR   MalaCards; CHST3; -.
DR   MIM; 143095; phenotype.
DR   MIM; 603799; gene.
DR   neXtProt; NX_Q7LGC8; -.
DR   OpenTargets; ENSG00000122863; -.
DR   Orphanet; 263463; CHST3-related skeletal dysplasia.
DR   PharmGKB; PA26503; -.
DR   eggNOG; ENOG410IIAV; Eukaryota.
DR   eggNOG; ENOG410YDA4; LUCA.
DR   GeneTree; ENSGT00530000062902; -.
DR   HOGENOM; HOG000261614; -.
DR   HOVERGEN; HBG106811; -.
DR   InParanoid; Q7LGC8; -.
DR   KO; K01020; -.
DR   OMA; SPQAREW; -.
DR   OrthoDB; EOG091G0V3Y; -.
DR   PhylomeDB; Q7LGC8; -.
DR   TreeFam; TF342871; -.
DR   BioCyc; MetaCyc:HS04610-MONOMER; -.
DR   BRENDA; 2.8.2.17; 2681.
DR   Reactome; R-HSA-2022870; Chondroitin sulfate biosynthesis.
DR   GenomeRNAi; 9469; -.
DR   PRO; PR:Q7LGC8; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000122863; -.
DR   CleanEx; HS_CHST3; -.
DR   Genevisible; Q7LGC8; HS.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0008459; F:chondroitin 6-sulfotransferase activity; IDA:UniProtKB.
DR   GO; GO:0001517; F:N-acetylglucosamine 6-O-sulfotransferase activity; IBA:GO_Central.
DR   GO; GO:0008146; F:sulfotransferase activity; TAS:ProtInc.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0030206; P:chondroitin sulfate biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006790; P:sulfur compound metabolic process; IDA:UniProtKB.
DR   InterPro; IPR016469; Carbohydrate_sulfotransferase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000863; Sulfotransferase_dom.
DR   Pfam; PF00685; Sulfotransfer_1; 1.
DR   PIRSF; PIRSF005883; Carbohydrate_sulfotransferase; 1.
DR   SUPFAM; SSF52540; SSF52540; 2.
PE   1: Evidence at protein level;
KW   Carbohydrate metabolism; Complete proteome; Disease mutation;
KW   Glycoprotein; Golgi apparatus; Membrane; Polymorphism;
KW   Reference proteome; Signal-anchor; Transferase; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN         1    479       Carbohydrate sulfotransferase 3.
FT                                /FTId=PRO_0000085188.
FT   TOPO_DOM      1     20       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     21     38       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     39    479       Lumenal. {ECO:0000255}.
FT   NP_BIND     141    147       PAPS. {ECO:0000250}.
FT   NP_BIND     301    309       PAPS. {ECO:0000250}.
FT   CARBOHYD     63     63       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     74     74       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     96     96       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    256    256       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    420    420       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    464    464       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VARIANT     222    222       R -> W (in SEDCJD; severely impairs or
FT                                abolishes the enzyme function;
FT                                dbSNP:rs121908617).
FT                                {ECO:0000269|PubMed:18513679}.
FT                                /FTId=VAR_047856.
FT   VARIANT     259    259       L -> P (in SEDCJD; severely impairs or
FT                                abolishes the enzyme function;
FT                                dbSNP:rs121908616).
FT                                {ECO:0000269|PubMed:18513679}.
FT                                /FTId=VAR_047857.
FT   VARIANT     304    304       R -> Q (in SEDCJD; reduced enzyme
FT                                activity; dbSNP:rs28937593).
FT                                {ECO:0000269|PubMed:15215498}.
FT                                /FTId=VAR_021413.
FT   VARIANT     307    307       L -> P (in SEDCJD; dbSNP:rs121908618).
FT                                {ECO:0000269|PubMed:18513679}.
FT                                /FTId=VAR_047858.
FT   VARIANT     348    348       I -> M (in dbSNP:rs3740128).
FT                                /FTId=VAR_021414.
FT   VARIANT     357    357       R -> Q (in dbSNP:rs3740129).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18513679}.
FT                                /FTId=VAR_021415.
FT   VARIANT     372    372       E -> K (in SEDCJD; dbSNP:rs267606734).
FT                                {ECO:0000269|PubMed:18513679}.
FT                                /FTId=VAR_047859.
FT   CONFLICT    387    387       R -> P (in Ref. 1; BAA32576).
FT                                {ECO:0000305}.
FT   CONFLICT    443    443       A -> P (in Ref. 1; BAA32576).
FT                                {ECO:0000305}.
SQ   SEQUENCE   479 AA;  54706 MW;  7C290DC4970F66E0 CRC64;
     MEKGLTLPQD CRDFVHSLKM RSKYALFLVF VVIVFVFIEK ENKIISRVSD KLKQIPQALA
     DANSTDPALI LAENASLLSL SELDSAFSQL QSRLRNLSLQ LGVEPAMEAA GEEEEEQRKE
     EEPPRPAVAG PRRHVLLMAT TRTGSSFVGE FFNQQGNIFY LFEPLWHIER TVSFEPGGAN
     AAGSALVYRD VLKQLFLCDL YVLEHFITPL PEDHLTQFMF RRGSSRSLCE DPVCTPFVKK
     VFEKYHCKNR RCGPLNVTLA AEACRRKEHM ALKAVRIRQL EFLQPLAEDP RLDLRVIQLV
     RDPRAVLASR MVAFAGKYKT WKKWLDDEGQ DGLREEEVQR LRGNCESIRL SAELGLRQPA
     WLRGRYMLVR YEDVARGPLQ KAREMYRFAG IPLTPQVEDW IQKNTQAAHD GSGIYSTQKN
     SSEQFEKWRF SMPFKLAQVV QAACGPAMRL FGYKLARDAA ALTNRSVSLL EERGTFWVT
//
